Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV000367781 | SCV000478502 | uncertain significance | Ehlers-Danlos syndrome type 7A | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001865247 | SCV002314161 | uncertain significance | Ehlers-Danlos syndrome, classic type, 1 | 2021-10-05 | criteria provided, single submitter | clinical testing | Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt COL5A1 protein function. ClinVar contains an entry for this variant (Variation ID: 365705). This variant has not been reported in the literature in individuals affected with COL5A1-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces glutamic acid with glycine at codon 122 of the COL5A1 protein (p.Glu122Gly). The glutamic acid residue is highly conserved and there is a moderate physicochemical difference between glutamic acid and glycine. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |